An observational study in Silver Russell Syndrome, Beckwith-Wiedemann Syndrome and Transient Neonatal Diabetes Mellitus, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 20 sites in France. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Angelman Syndrome with a site in France — 3 open to participants now, 4 under way, none of them phase 3. Angelman Syndrome · France.
Among the 10 studies in Angelman Syndrome with a site in France, this one is the only one that started in 2017, is one of 4 observational ones, and was the 7th registered.
52 studies on the registry are indexed under Angelman Syndrome; 16 are open to participants now.
Browse Angelman Syndrome studies →3 of the 10 studies in Angelman Syndrome with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 3–17
University Hospital, Toulouse · Sites in France
Ages 3–50
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 14 Angelman Syndrome studies recruiting now, 6 (43%) set no upper age limit and 7 (50%) stop at 75 or younger; 14 take children under 18; none take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 2
First in 2007; this study’s year is marked. 1 started in 2017.
This study's planned enrollment of 2,000 is above the median of 120 across 21 observational studies indexed under Angelman Syndrome.
Median enrollment 69 across the 6 interventional studies, 421 across the 4 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 7 most frequent:
Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.
Institut National de la Santé Et de la Recherche Médicale, France has 1 study filed under Angelman Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Angelman Syndrome with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06737718Assistance Publique - Hôpitaux de ParisUse of Eye Tracking to Study Social Perception Abnormalities in Children With Angelman Syndrome | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Angelman Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to describe the natural history of imprinting disorders (IDs) according to their metabolic profile in all patients (adults and children) affected with an ID regardless of the severity of the disease, with a molecular characterization, with a signed informed consent for all subjects, followed in one partner's center.
The main questions it aims to answer are:
All patients (adults and children) affected with an ID regardless of the severity of the disease, with a molecular characterization, with a signed informed consent for all subjects, followed in one partner's center.
Inclusion Criteria:
Non-Inclusion Criteria:
There are no non-inclusion criteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The clinical characteristics of IDs in pediatric and adult's patients.
Time frame: Through study completion, an average of 10 years
The genetic characteristics of IDs in pediatric and adult's patients.
Time frame: Through study completion, an average of 10 years
The biological characteristics of IDs in pediatric and adult's patients.
Time frame: Through study completion, an average of 10 years
The morphometric characteristics of IDs in pediatric and adult's patients.
Time frame: Through study completion, an average of 10 years
Search for an association between the metabolic phenotype of IDs patients' and their biological profil.
Time frame: At the time of diagnosis (or at first measurement)
Determination of the prevalence of metabolic abnormalities (MA).
Time frame: At inclusion
Estimation of the risk for metabolic complications such as obesity, diabetes, cardiovascular disease (CVD), metabolic syndrome.
Time frame: 10 years after
Description of different therapeutic approaches and identification of a common base for all IDs.
Time frame: Through study completion, an average of 10 years
Variations of quality-of-life scores.
Time frame: Through study completion, an average of 10 years
Analyse of (epi)genetic mutations transmission in proband and relatives.
Time frame: Through study completion, an average of 10 years
Identification of different metabolic profile which allow a clinical classification of IDs.
Time frame: Through study completion, an average of 10 years
Description and identification of the most relevant biological and clinical practices for diagnostic and follow-up of ID patients.
Time frame: Through study completion, an average of 10 years
Identification of a group of French patients with the same characteristics.
Time frame: At inclusion
Search of an association between blood metabolic markers, genetic pattern and gut microbiota.
Time frame: Through study completion, an average of 10 years
Description of different scientific rational for transferring a therapeutic approach (clinical guidelines) from an ID to another (identification of common phenotype, i.e. metabolic profile).
Time frame: Through study completion, an average of 10 years
Started Mar 2017 (actual). Primary completion is estimated for Mar 2028, 132 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut National de la Santé Et de la Recherche Médicale, France →